^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

SCR9168

i
Other names: SCR9168, SCR 9168, SCR-9168
Associations
Trials
Company:
Simcere
Drug class:
CD47 inhibitor
Associations
Trials
over1year
Generation of a mutant SIRPa fusion protein with highly-improved affinity and favorable safety profile (AACR 2023)
SCR9168 demonstrates the best-in-class potential among SIRPα mutein molecules. It elicits improved and dose-dependent efficacy in phagocytosis or tumor suppression combining with therapeutic antibodies, such as trastuzumab or cetuximab. Favorable safety profile with no phagocytosis of RBC or platelets in vitro as well as no hematological toxicity observation in cynomolgus monkeys allows broader dose range exploration in early clinical phase.
Clinical
|
CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
|
CD47 expression
|
Herceptin (trastuzumab) • Erbitux (cetuximab) • SCR9168